25 mg etanercept once weekly in rheumatoid arthritis and spondylarthropathy

Joint Bone Spine

Volumn 74, Issue 2, 2007, Pages 144-147

  Berthelot, Jean Marie ^a   Varin, Stéphane ^a   Cormier, Grégoire ^a   Tortellier, Laetitia ^a   Guillot, Pascale ^a   Glemarec, Joëlle ^a   Maugars, Yves ^a  

^a HÔTEL DIEU   (France)

Author keywords

25 mg; BASDAI; DAS28; Dosing; Etanercept; Rheumatoid arthritis; Spondylarthropathy

Indexed keywords

ETANERCEPT;

ADULT; ARTICLE; HUMAN; MAJOR CLINICAL STUDY; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SPONDYLARTHROPATHIES; TREATMENT OUTCOME;

EID: 34247129743     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2006.03.010     Document Type: Article

References (20)

1. Khanna D., McMahon M., and Furst D.E. Safety of tumor necrosis factor-alpha antagonists. Drug Saf 27 (2004) 307-324
2. Geborek P., Bladstrom A., Turesson C., Gulfe A., Petersson I.F., Saxne T., et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64 (2005) 699-703
3. Symmons D.P.M. Anti-tumour necrosis factor alpha therapy: can we afford it?. Ann Rheum Dis 64 (2005) 969-970
4. Felson D.T., Anderson J.J., Lange M.L., Wells G., and LaValley M.P. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?. Arthritis Rheum 41 (1998) 1564-1570
5. Fraenkel L., Bogardus S., Concato J., and Felson D. Unwillingness of rheumatoid arthritis patients to risk adverse effects. Rheumatology 41 (2002) 253-261
6. Brocq O., Plubel Y., Breuil V., Grisot C., Flory P., Mousnier A., et al. Etanercept-infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti-TNFalpha. Presse Med 31 (2002) 1836-1839
7. van Vollenhoven R., Harju A., Brannemark S., and Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice-versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense. Ann Rheum Dis 62 (2003) 1195-1198
8. Hansen K.E., Hildebrand J.P., Genovese M.C., Cush J.J., Patel S., Cooley D.A., et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 31 (2004) 1098-1102
9. Den Broeder A.A., Creemers M.C., van Gestel A.M., and van Riel P.L. Dose titration using the disease activity score (DAS28) in rheumatoid arthritis patients treated with anti-TNF alpha. Rheumatology 41 (2002) 638-642
10. Clunie G., Voules S., and Watts R. Dose reduction of etanercept: can we treat more patients using a fixed budget?. Rheumatology 42 (2003) 600-601
11. Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ?. Semin Arthritis Rheum 34 Suppl 1 (2005) 12-18
12. Berthelot J.M., and Varin S. Is dosage reduction appropriate in patients who respond well to anti-TNF-alpha agents?. Joint Bone Spine 71 (2004) 545-548
13. Genovese M.C., Cohen S., Moreland L., Lium D., Robbins S., Newmark R., et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 50 (2004) 1412-1419
14. Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., Keystone E.C., et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Eng J Med 343 (2000) 1586-1593
15. Landewe R., van der Heijde D., van Vollenhoven R., Fatenejad S., and Klareskog L. A disconnect between inflammation and radiographic progression in patients treated with etanercept plus methotrexate and etanercept alone as compared to methotrexate alone. Results from the Tempo-trial. Arthritis Rheum 52 Suppl (2005) S343
16. van Vollenhoven R.F., Gudbrandsdottir S., Jonsdottir T., Muller K., Klareskog L., Bendtzen K., et al. Correlation between free serum etanercept levels and clinical response to treatment in rheumatoid arthritis. Arthritis Rheum 52 Suppl (2005) 134
17. Kobelt G., Lindgren P., Singh A., and Klareskog L. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis 64 (2005) 1174-1179
18. Pham T., Guillemin F., Claudepierre P., Luc M., Miceli-Richard C., Fautrel B., et al. TNFα antagonist therapy in ankylosing spondylitis and psoriatic arthritis: recommendations of the French Society for Rheumatology. Joint Bone Spine 73 (2006) 547-553
19. Fautrel B., Constantin A., Morel J., Vittecoq O., Cantagrel A., Combe B., et al. Recommendations of the French Society for Rheumatology. TNFα antagonist therapy in rheumatoid arthritis. Joint Bone Spine 73 (2006) 433-441
20. Kamal K.M., Madhavan S.S., Hornsby J.A., Miller L.A., Kavookjian J., and Scott V. Use of tumor necrosis factor inhibitors in rheumatoid arthritis: a national survey of practicing United States rheumatologists. Joint Bone Spine 73 (2006) 718-724